RESUMO
BACKGROUND: Community-acquired (CA) and healthcare-associated (HCA) infections caused by carbapenemase-producing Enterobacterales (CPE) are not well characterized. The objective was to provide detailed information about the clinical and molecular epidemiological features of nosocomial, HCA and CA infections caused by carbapenemase-producing Klebsiella pneumoniae (CP-Kp) and Escherichia coli (CP-Ec). METHODS: A prospective cohort study was performed in 59 Spanish hospitals from February to March 2019, including the first 10 consecutive patients from whom CP-Kp or CP-Ec were isolated. Patients were stratified according to acquisition type. A multivariate analysis was performed to identify the impact of acquisition type in 30-day mortality. RESULTS: Overall, 386 patients were included (363 [94%] with CP-Kp and 23 [6%] CP-Ec); in 296 patients (76.3%), the CPE was causing an infection. Acquisition was CA in 31 (8.0%) patients, HCA in 183 (47.4%) and nosocomial in 172 (48.3%). Among patients with a HCA acquisition, 100 (54.6%) had been previously admitted to hospital and 71 (38.8%) were nursing home residents. Urinary tract infections accounted for 19/23 (82.6%), 89/130 (68.5%) and 42/143 (29.4%) of CA, HCA and nosocomial infections, respectively. Overall, 68 infections (23%) were bacteremia (8.7%, 17.7% and 30.1% of CA, HCA and nosocomial, respectively). Mortality in infections was 28% (13%, 14.6% and 42.7% of CA, HCA and nosocomial, respectively). Nosocomial bloodstream infections were associated with increased odds for mortality (adjusted OR, 4.00; 95%CI 1.21-13.19). CONCLUSIONS: HCA and CA infections caused by CPE are frequent and clinically significant. This information may be useful for a better understanding of the epidemiology of CPE.
RESUMO
This large, multicenter, retrospective cohort study including onco-hematological neutropenic patients with Pseudomonas aeruginosa bloodstream infection (PABSI) found that among 1213 episodes, 411 (33%) presented with septic shock. The presence of solid tumors (33.3% vs. 20.2%, p < 0.001), a high-risk Multinational Association for Supportive Care in Cancer (MASCC) index score (92.6% vs. 57.4%; p < 0.001), pneumonia (38% vs. 19.2% p < 0.001), and infection due to multidrug-resistant P. aeruginosa (MDRPA) (33.8% vs. 21.1%, p < 0.001) were statistically significantly higher in patients with septic shock compared to those without. Patients with septic shock were more likely to receive inadequate empirical antibiotic therapy (IEAT) (21.7% vs. 16.2%, p = 0.020) and to present poorer outcomes, including a need for ICU admission (74% vs. 10.5%; p < 0.001), mechanical ventilation (49.1% vs. 5.6%; p < 0.001), and higher 7-day and 30-day case fatality rates (58.2% vs. 12%, p < 0.001, and 74% vs. 23.1%, p < 0.001, respectively). Risk factors for 30-day case fatality rate in patients with septic shock were orotracheal intubation, IEAT, infection due to MDRPA, and persistent PABSI. Therapy with granulocyte colony-stimulating factor and BSI from the urinary tract were associated with improved survival. Carbapenems were the most frequent IEAT in patients with septic shock, and the use of empirical combination therapy showed a tendency towards improved survival. Our findings emphasize the need for tailored management strategies in this high-risk population.
RESUMO
OBJECTIVES: Information is scarce on clinical experiences with non-neutropenic patients with invasive fungal infection (IFI) receiving isavuconazole. We aimed to report the safety and effectiveness of this drug as a first-line treatment or rescue in real life. METHODS: A retrospective, observational multicentric study of non-neutropenic patients who received isavuconazole as an IFI treatment at 12 different university hospitals (January 2018-2022). All patients met criteria for proven, probable or possible IFI according to EORTC-MSG. RESULTS: A total of 238 IFIs were treated with isavuconazole during the study period. Combination therapy was administered in 27.7% of cases. The primary IFI was aspergillosis (217, 91.2%). Other IFIs treated with isavuconazole were candidemia (n = 10), mucormycosis (n = 8), histoplasmosis (n = 2), cryptococcosis (n = 2), and others (n = 4). Median time of isavuconazole treatment was 29 days. Only 5.9% (n = 14) of cases developed toxicity, mainly hepatic-related (10 patients, 4.2%). Nine patients (3.8%) had treatment withdrawn. Successful clinical response at 12 weeks was documented in 50.5% of patients. CONCLUSION: Isavuconazole is an adequate treatment for non-neutropenic patients with IFIs. Toxicity rates were low and its effectiveness was comparable to other antifungal therapies previously reported.
Assuntos
Antifúngicos , Infecções Fúngicas Invasivas , Nitrilas , Piridinas , Triazóis , Humanos , Nitrilas/uso terapêutico , Nitrilas/efeitos adversos , Piridinas/uso terapêutico , Piridinas/efeitos adversos , Estudos Retrospectivos , Antifúngicos/uso terapêutico , Antifúngicos/efeitos adversos , Feminino , Masculino , Pessoa de Meia-Idade , Triazóis/uso terapêutico , Triazóis/efeitos adversos , Idoso , Infecções Fúngicas Invasivas/tratamento farmacológico , Adulto , Resultado do Tratamento , Idoso de 80 Anos ou mais , Aspergilose/tratamento farmacológico , Adulto JovemRESUMO
OBJECTIVES: To assess the mortality attributable to infections caused by carbapenem-resistant Enterobacterales (CRE) and to investigate the effect of clinical management on differences in observed outcomes in a multinational matched cohort study. METHODS: A prospective matched-cohorts study (NCT02709408) was performed in 50 European hospitals from March 2016 to November 2018. The main outcome was 30-day mortality with an active post-discharge follow-up when applied. The CRE cohort included patients with complicated urinary tract infections, complicated intra-abdominal infections, pneumonia, or bacteraemia from other sources because of CRE. Two control cohorts were selected: patients with infection caused by carbapenem-susceptible Enterobacterales (CSE) and patients without infection. Matching criteria included type of infection for the CSE group, hospital ward of CRE detection, and duration of hospital admission up to CRE detection. Multivariable and stratified Cox regression was applied. RESULTS: The cohorts included 235 patients with CRE infection, 235 patients with CSE infection, and 705 non-infected patients. The 30-day mortality (95% CI) was 23.8% (18.8-29.6), 10.6% (7.2-15.2), and 8.4% (6.5-10.6), respectively. The difference in 30-day mortality rates between patients with CRE infection when compared with patients with CSE infection was 13.2% (95% CI, 6.3-20.0), (HR, 2.57; 95% CI, 1.55-4.26; p < 0.001), and 15.4% (95% CI, 10.5-20.2) when compared with non-infected patients (HR, 3.85; 95% CI, 2.57-5.77; p < 0.001). The population attributable fraction for 30-day mortality for CRE vs. CSE was 19.28%, and for CRE vs. non-infected patients was 9.61%. After adjustment for baseline variables, the HRs for mortality were 1.87 (95% CI, 0.99-3.50; p 0.06) and 3.65 (95% CI, 2.29-5.82; p < 0.001), respectively. However, when treatment-related time-dependent variables were added, the HR of CRE vs. CSE reduced to 1.44 (95% CI, 0.78-2.67; p 0.24). DISCUSSION: CRE infections are associated with significant attributable mortality and increased adjusted hazard of mortality when compared with CSE infections or patients without infection. Underlying patient characteristics and a delay in appropriate treatment play an important role in the CRE mortality.
Assuntos
Assistência ao Convalescente , Gammaproteobacteria , Humanos , Estudos de Coortes , Alta do Paciente , Estudos Prospectivos , Carbapenêmicos/farmacologia , Carbapenêmicos/uso terapêutico , Estudos de Casos e ControlesRESUMO
BACKGROUND: Significant variations in the variables collected in clinical studies focusing on bacteraemia lead to inconsistency in the evaluation of risk factors for mortality. OBJECTIVE: We aimed to define a minimum set of risk factors that should be assessed and reported in all studies assessing survival in bacteraemia. STUDY ELIGIBILITY: We conducted a systematic review including observational prospective and retrospective cohort studies that assessed all-cause mortality among patients with bacteraemia. We included only studies computing an adjusted analysis for mortality, with >500 participants. EXPOSURES: Independently significant risk factors for all-cause, preferably 30-day, mortality. DATA SOURCES: PubMed was used to identify eligible studies published between 2000 and 2020. A Delphi survey among experts was used to evaluate and prioritize the factors identified by the systematic review. RISK OF BIAS: SIGN checklist complemented by risk of bias assessment of the adjusted analysis. DATA SYNTHESIS: Definite universal risk factors were defined as those assessed in >50% of all included studies and significant in >50% of those. Potential universal risk factors were defined as those significant in >50% of studies evaluating the factor and a subgroup analysis was performed for studies of Staphylococcus aureus bacteraemia. RESULTS: We included in the systematic review 62 studies, comprising more than 300,000 patients, from which a list of 17 risk factors was derived, whose association with all-cause mortality was statistically significant in most studies. The factors address baseline patient variables, the setting of infection acquisition, factors associated with the specific infection, the inflammatory response at onset of sepsis and management parameters where relevant. There were 14 risk factors for S. aureus bacteraemia. CONCLUSION: We identified a minimum set of universal factors to be collected, reported, and assessed, in all future studies evaluating factors associated with mortality in bacteraemia to improve study quality and harmonization.
Assuntos
Bacteriemia , Técnica Delphi , Humanos , Bacteriemia/mortalidade , Fatores de Risco , Infecções Estafilocócicas/mortalidade , Estudos ProspectivosRESUMO
[This corrects the article DOI: 10.3389/fmicb.2022.918362.].
RESUMO
INTRODUCCIÓN: El diagnóstico tardío (DT) de la infección por el VIH se asocia con un aumento de su morbimortalidad y su transmisibilidad. El objetivo de este estudio fue definir las características clínicas de los nuevos diagnósticos y clarificar los factores de riesgo (FR) asociados al DT con o sin enfermedad avanzada (EA) entre el año 2014 y 2018. MÉTODOS: Se incluyeron a los pacientes con nuevo diagnóstico de infección por el VIH atendidos en una consulta especializada de un hospital de tercer nivel. El DT con o sin EA se definió como el recuento de CD4 < 350 cel/mm3 o CD4 < 200 cel/mm3 respectivamente y/o condición definitoria de sida al diagnóstico. Se realizó un análisis mediante regresión logística binaria para analizar los FR asociados al DT y a la EA. RESULTADOS: De los 205 nuevos diagnósticos, 102 (50%) fueron DT. La edad ≥32 años [(OR, IC95%); 2,92 (1,52-5,59)], la transmisión distinta a la de hombres que tienen sexo con hombres [3,39 (1,56-7,34)] y la hospitalización en el diagnóstico [9,68 (2,63-35,68)] fueron FR asociados al DT. Por otro lado, tener una enfermedad de transmisión sexual (ETS) concomitante [0,37 (0,17-0,77)] se asoció con un diagnóstico precoz. Los resultados fueron similares al analizar el DT con EA excepto para la ETS. CONCLUSIÓN: El conocimiento de las características clínicas y epidemiológicas de los nuevos diagnósticos de infección por el VIH y de los FR para el DT con o sin EA constituyen una oportunidad para el diagnóstico precoz y para disminuir la transmisibilidad
INTRODUCTION: Late diagnosis (LD) of HIV infection is associated with an increase in morbidity and mortality and transmissibility. The aim of this study was to define the clinical characteristics of new diagnoses and clarify the risk factors (RF) associated with LD with or without advanced disease (AD) between 2014 and 2018. METHODS: Patients with a new diagnosis of HIV infection treated in a specialised outpatient clinic of a third level hospital were included. LD with or without AD was defined as aCD4 count < 350 cel/mm3 or CD4 < 200 cel/mm3 respectively and/or the presence of any AIDS condition on diagnosis. An analysis was performed using binary logistic regression to analyse the RF associated with LD and the AD. RESULTS: Of the 205 new diagnoses, 102 (50%) were LD. Age ≥ 32 years [(OR, 95% CI); 2.92 (1.52-5.59)], transmission different than in men who have sex with men [3.39 (1.56-7.34)] and hospitalisation on diagnosis [9.68 (2.63-35.68)] were RF associated with LD. On the other hand, having a concomitant sexually transmitted disease (STD) [.37 (.17-.77)] was associated with an early diagnosis. The results were similar when analysing the LD with AD except for the STD. CONCLUSION: Knowledge of the clinical and epidemiological characteristics of new diagnoses of HIV infection and of the RF for LD with or without AD provides an opportunity for early diagnosis and to reduce transmissibility
Assuntos
Humanos , Masculino , Feminino , Adulto , Infecções por HIV/diagnóstico , Diagnóstico Tardio , Infecções por HIV/epidemiologia , Fatores de Risco , Indicadores de Morbimortalidade , Modelos Logísticos , Diagnóstico Precoce , Estudos RetrospectivosRESUMO
No disponible